Internal Medicine

Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.

Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.

The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.

The new findings break ground on placebo-controlled assessment of the PCSK9 inhibitor for the pediatric population.

Up to 91% patients who received maximum dosage of the drug achieved a triglyceride level of <150 mg/dL, according to new data presented at ESC 2020.

A look at how asymptomatic AFib is being combatted by consumer devices and embraced, large-scale population research.

New cohort analyses show very few patients with atrial fibrillation exercise regularly or rigorously—which could be a detriment to their mortality risk.

Daniel Gaudet, MD, PhD, discusses what's next in clinical pursuits of the greatly underdiagnosed hereditary cardiovascular disease.

Investigators simulated baseline CV risk and predicted potential risk reduction among a cohort of evolocumab users across Europe.

Racial and ethnic disparities did not substantially improve between 2005-2015 for patients with end-stage kidney disease.

A podcast interview with the president of American Society of Preventive Cardiology, on the eve of the ESC 2020 Congress.

COVID-19 positive patients with COPD demonstrated a greater risk for hospitalization, ICU admission, and need for invasive mechanical ventilation compared with non-COPD patients.

Antithrombotic agents caused 34% of serious adverse drug reactions identified in the study.

J. John Mann, MD, discusses potential next steps for further assessment of ketamine's antidepressant effects.

Telemedicine could be something that is still used, even after the COVID-19 pandemic is over.

Approximately 11.7% of nearly 90,000 hospitalized patients with confirmed influenza suffered from an acute cardiovascular event.

Blood supply shortages have underscored a need to develop new strategies which limit transfusions and triage blood products.

An expert discusses ALKS 3831, a potential new treatment that demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

Tricida will meet with the FDA in an attempt to provide more data for the treatment of patients with chronic kidney disease.

J. John Mann, MD, discusses findings in a new study that uncovers the mechanisms behind Ketamine's antidepressant effect.

A new survey assessed patients’ confidence in their disease management during the pandemic, specific disease management concerns, and experiences with telemedicine.

Considerable discrepancy found between overt clinical symptoms of laryngeal pathology and abnormalities observed during a task protocol.

No life-threatening adverse events occurred in the 150 patient trial to treat non-alcoholic fatty liver disease.

J. John Mann, MD, compares esketamine nasal spray to intravenous administration and explains the drawbacks of the newly approved treatment method for MDD.

The risk of developing fibrosis and macular atrophy increased based on which quartile of foveal center point thickness standard deviation an individual falls in.